Data as of Apr 16
| +0.26 / +2.12%|
The 2 analysts offering 12-month price forecasts for Oramed Pharmaceuticals Inc have a median target of 31.00, with a high estimate of 35.00 and a low estimate of 27.00. The median estimate represents a +147.21% increase from the last price of 12.54.
The current consensus among 2 polled investment analysts is to Buy stock in Oramed Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.